NO142666C - Analogifremgangsmaate ved fremstilling av terapeutisk aktive 1-aryloxy-4-amino-2-butanoler - Google Patents

Analogifremgangsmaate ved fremstilling av terapeutisk aktive 1-aryloxy-4-amino-2-butanoler

Info

Publication number
NO142666C
NO142666C NO753575A NO753575A NO142666C NO 142666 C NO142666 C NO 142666C NO 753575 A NO753575 A NO 753575A NO 753575 A NO753575 A NO 753575A NO 142666 C NO142666 C NO 142666C
Authority
NO
Norway
Prior art keywords
butanols
aryloxy
amino
preparation
therapeutic active
Prior art date
Application number
NO753575A
Other languages
English (en)
Norwegian (no)
Other versions
NO753575L (es
NO142666B (no
Inventor
Carl Dalton Lunsford
Ying Ho Chen
Original Assignee
Robins Co Inc A H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Robins Co Inc A H filed Critical Robins Co Inc A H
Publication of NO753575L publication Critical patent/NO753575L/no
Publication of NO142666B publication Critical patent/NO142666B/no
Publication of NO142666C publication Critical patent/NO142666C/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00Ethers; Compounds having groups, groups or groups
    • C07C43/02Ethers
    • C07C43/18Ethers having an ether-oxygen atom bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C43/196Ethers having an ether-oxygen atom bound to a carbon atom of a ring other than a six-membered aromatic ring containing hydroxy or O-metal groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00Ethers; Compounds having groups, groups or groups
    • C07C43/02Ethers
    • C07C43/20Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
NO753575A 1974-10-25 1975-10-24 Analogifremgangsmaate ved fremstilling av terapeutisk aktive 1-aryloxy-4-amino-2-butanoler NO142666C (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51812274A 1974-10-25 1974-10-25
US61898475A 1975-10-02 1975-10-02

Publications (3)

Publication Number Publication Date
NO753575L NO753575L (es) 1976-04-27
NO142666B NO142666B (no) 1980-06-16
NO142666C true NO142666C (no) 1981-09-17

Family

ID=27059352

Family Applications (1)

Application Number Title Priority Date Filing Date
NO753575A NO142666C (no) 1974-10-25 1975-10-24 Analogifremgangsmaate ved fremstilling av terapeutisk aktive 1-aryloxy-4-amino-2-butanoler

Country Status (21)

Country Link
JP (1) JPS6023100B2 (es)
AU (1) AU507312B2 (es)
BR (1) BR7506930A (es)
CA (1) CA1077474A (es)
CH (1) CH612907A5 (es)
DE (1) DE2547570A1 (es)
DK (1) DK154288C (es)
ES (1) ES442077A1 (es)
FI (1) FI60201C (es)
FR (2) FR2289169A1 (es)
GB (1) GB1520931A (es)
HU (1) HU172525B (es)
IE (1) IE43402B1 (es)
IL (1) IL48309A (es)
IN (1) IN142736B (es)
NL (1) NL7512488A (es)
NO (1) NO142666C (es)
NZ (1) NZ178962A (es)
PH (2) PH16403A (es)
SE (2) SE434047B (es)
YU (1) YU39950B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE115953T1 (de) * 1987-12-11 1995-01-15 Mitsui Petrochemical Ind Amine und deren verwendung.
DE4108527A1 (de) * 1991-03-15 1992-09-17 Basf Ag Neue 1-(4-cyano-4-aryl-cyclohexyl)piperazine, ihre herstellung und verwendung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1245148A (en) * 1968-11-18 1971-09-08 Pfizer Ltd Propanolamine derivatives
SE384853B (sv) * 1972-04-04 1976-05-24 Haessle Ab Forfarande for framstellning av nya aminer
DE2001431C3 (de) * 1970-01-06 1974-12-12 Helopharm W. Petrik & Co Kg, 1000 Berlin 2-(2'-Hydroxy-3'-alkylaminopropoxy)-Omega-phenyl-propiophenone und Verfahren zur Herstellung derselben
HU169464B (es) * 1974-02-20 1976-11-28

Also Published As

Publication number Publication date
ES442077A1 (es) 1977-04-01
FI752966A (es) 1976-04-26
CA1077474A (en) 1980-05-13
PH16233A (en) 1983-08-11
DK480675A (da) 1976-04-26
AU8577875A (en) 1977-04-21
NZ178962A (en) 1978-03-06
YU39950B (en) 1985-06-30
FR2361888B1 (es) 1980-04-04
FI60201B (fi) 1981-08-31
CH612907A5 (en) 1979-08-31
DK154288C (da) 1989-03-28
HU172525B (hu) 1978-09-28
SE449357B (sv) 1987-04-27
IE43402B1 (en) 1981-02-25
NO753575L (es) 1976-04-27
JPS6023100B2 (ja) 1985-06-05
JPS51131838A (en) 1976-11-16
FR2289169B1 (es) 1980-05-30
AU507312B2 (en) 1980-02-14
GB1520931A (en) 1978-08-09
DE2547570A1 (de) 1976-04-29
BR7506930A (pt) 1976-08-17
SE7511934L (sv) 1976-04-26
PH16403A (en) 1983-09-26
IE43402L (en) 1976-04-25
FI60201C (fi) 1981-12-10
NO142666B (no) 1980-06-16
IL48309A (en) 1980-01-31
SE7903894L (sv) 1979-05-04
IN142736B (es) 1977-08-20
IL48309A0 (en) 1975-12-31
DK154288B (da) 1988-10-31
NL7512488A (nl) 1976-04-27
FR2361888A1 (fr) 1978-03-17
FR2289169A1 (fr) 1976-05-28
YU269475A (en) 1982-02-28
SE434047B (sv) 1984-07-02

Similar Documents

Publication Publication Date Title
NO143576C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive heterocykliske forbindelser
NO141407C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive etylenderivater
NO145691C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme decapeptidamider
NO149106C (no) Analogifremgangsmaate for fremstilling av farmakologisk aktive benzcykloamider
NO143460C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzomorfaner.
NO141800C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzomorfaner.
NO151040C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5-halogenpyrimid-2-oner
NO147109C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive diazepin-derivater
NO146359C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive cyproheptadinderivater
NO142838C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive isokinolinderivater
NO141894C (no) Analogifremgangsmaate for fremstilling av farmakologisk aktive pyridobenzodiazepinoner
NO144108C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive n-(1-benzylpiperid-4-yl)-benzamider
NO143064C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive hydroksyalkylxantiner
NO146060C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 2-substituerte-5-alkylresorcinol
NO143664C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive dibenzofuranforbindelser
NO147485C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 8-aminomethylisoflavonderivater
NO145163C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive antitumorglykosider
NO142077C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive n-(1-cyclohexyl-3-pyrrolidinyl)-benzamider
NO145238C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive dihydrokarbostyril-derivater
NO144704C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 1-alkyl-2-(fenoksymetyl)-5-nitro-imidazoler
NO145620C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive depotsteroidestere.
NO144110C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 5:6-benzo-4-pyron-derivater
NO146672C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive cinnolinderivater
NO143903C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5-fluorpyrimidin-4-on-derivater
NO144741C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiopyrano-pyrazoler